Ra Pharmaceuticals, Inc. Common Stock
RARX
RARX was delisted on the 1st of April, 2020.
0 hedge funds and large institutions have $0 invested in Ra Pharmaceuticals, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $32K → $0 (-$32K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Daiwa Securities Group
Tokyo,
Japan
|
-$32K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Daiwa Securities Group
Tokyo,
Japan
| – | -$32K | -266 | Closed |
|
RARX Hedge Fund Activity: Q3 2020 in Review
0 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Ra Pharmaceuticals, Inc. Common Stock (RARX) for Q3 2020, worth a combined $0 — down 100% from $32K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of RARX and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Daiwa Securities Group, exiting entirely with an estimated $32K sold.
- 0 institutional investors held Ra Pharmaceuticals, Inc. Common Stock (RARX) as of Q3 2020, down from 1 in Q2 2020.
- Funds reported $0 of Ra Pharmaceuticals, Inc. Common Stock stock for Q3 2020, down 100% quarter-over-quarter.
- 0 funds opened new Ra Pharmaceuticals, Inc. Common Stock positions in Q3 2020 and 1 closed out, a net change of -1 holder.
- The largest Ra Pharmaceuticals, Inc. Common Stock seller in Q3 2020 was Daiwa Securities Group, an estimated $32K sold.
Based on aggregated 13F filings for Q3 2020.